Develops eye care drugs for Demodex blepharitis and ocular rosacea.
Jun 2026Revenue $606M/yrExpenses $655M/yr
No trend
Figures by year
When will Tarsus Pharmaceuticals be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $606M and expenses $655M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $451M | $522M | −$71.0M |
| Dec 2024 | $183M | $304M | −$121M |
| Dec 2023 | $17.4M | $161M | −$143M |
| Dec 2022 | $25.8M | $88.5M | −$62.7M |
| Dec 2021 | $57.0M | $69.2M | −$12.2M |
| Dec 2020 | $0.00 | $27.0M | −$27.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.